Outrage Grows as CDC Moves Forward With Controversial Hepatitis B Vaccine Study
The CDC allocates $1.6 million for a study on alleged harms of the hepatitis B vaccine, drawing criticism from experts who call it unethical.
Headline and summary written by an AI model from the linked articles; not reviewed by a person. How this was made
This story has stopped developing; this page is its permanent record. More from that day
The odds
Each tick is a source publishing on this story · 1 more published before price tracking began
Price data
| Time | Chance of yes |
|---|---|
| now | 4% |
| 8 Oct, 19:24 UTC | 4% |
The story so far
2 publishers have covered this in 2 articles since 8 Oct 2026. Rolling Stone published first, on 8 October at 00:00 UTC; Ars Technica followed 43h 27m later. The most recent article, from Ars Technica, appeared on 9 October at 19:27 UTC.
Outlets reporting it: Ars Technica (major outlet), Rolling Stone.
One prediction market prices this story:
- Hepatitis B — the market puts it at 4%, closing 1 Jan 2027. The outcome is Yes if the CDC completely stops recommending the Hepatitis B vaccine before January 1, 2027. Otherwise, the outcome is No. Readers often mistake public outrage or study controversies for an official change in CDC guidelines.
Odds are the market's probability that the outcome happens, updated every few minutes. They are information about what traders expect, not a forecast we make and not investment advice.
Sources
Every article we clustered into this story. Headlines link to the publisher.
Related prediction markets
Linked by software because they are about the same subject. Most ask a different question from the one this story reports, so read each market's own question. How often the link is right
- Kalshi Hepatitis B 4%
Does the market have this right?
Wrong market?
Have your say
Your call. How does this end?
Free, no money involved. Calls are scored against the market's price when you make them, so backing an underdog that wins scores most. Leaderboard · Your calls
Email me when the odds move
In this story
- CDC
- Paul Offit